Dupuytren's Disease
0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
PfizerNEW YORK, NY
1 programRegistry of Dupuytren's Contracture Treatment OutcomesN/A1 trial
Active Trials
United TherapeuticsMD - Silver Spring
1 programAdalimumabPHASE_2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
United TherapeuticsAdalimumab
Verona PharmaMiniFlo
PfizerRegistry of Dupuytren's Contracture Treatment Outcomes
Clinical Trials (3)
Total enrollment: 245 patients across 3 trials
Repurposing Anti-TNF for Treating Dupuytren's Disease
Start: Mar 2016Est. completion: Dec 2020140 patients
Phase 2Completed
MiniFlo for Advanced Dupuytren's Disease
Start: Aug 2014Est. completion: May 201618 patients
N/ACompleted
Registry of Dupuytren's Contracture Treatment Outcomes
Start: Dec 2011Est. completion: Apr 201387 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.